GRI Bio, Inc. — Director's Dealing 2022

Dec 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vallon Pharmaceuticals, Inc. (VLON)
CIK: 0001824293
Period of Report: 2022-12-13

Reporting Person: Thorell Marella (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-13	Common Stock	J	28517	—	Disposed	9506	Direct

Footnotes

F1: Cancellation of unvested restricted stock units granted on July 1, 2022.